Pinnacle Associates Ltd. Trims Stake in Thermo Fisher Scientific Inc. $TMO

Pinnacle Associates Ltd. decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 21,637 shares of the medical research company’s stock after selling 2,449 shares during the period. Pinnacle Associates Ltd.’s holdings in Thermo Fisher Scientific were worth $12,537,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. E Fund Management Hong Kong Co. Ltd. grew its stake in Thermo Fisher Scientific by 13,800.0% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 417 shares of the medical research company’s stock worth $243,000 after purchasing an additional 414 shares in the last quarter. Plancorp LLC increased its position in Thermo Fisher Scientific by 4.8% during the 4th quarter. Plancorp LLC now owns 1,120 shares of the medical research company’s stock valued at $649,000 after purchasing an additional 51 shares during the period. Western Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 32.6% in the 4th quarter. Western Wealth Management LLC now owns 4,494 shares of the medical research company’s stock worth $2,604,000 after purchasing an additional 1,104 shares during the period. Castle Rock Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 2.1% during the fourth quarter. Castle Rock Wealth Management LLC now owns 3,667 shares of the medical research company’s stock valued at $2,091,000 after purchasing an additional 76 shares in the last quarter. Finally, Proactive Wealth Strategies LLC raised its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. Proactive Wealth Strategies LLC now owns 745 shares of the medical research company’s stock worth $432,000 after buying an additional 30 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This represents a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on TMO shares. Wall Street Zen cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Royal Bank Of Canada set a $490.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday. TD Cowen decreased their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a report on Friday, January 30th. Morgan Stanley restated an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Finally, Barclays lowered their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $616.10.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $448.12 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The business has a fifty day moving average of $487.50 and a 200 day moving average of $542.85. The firm has a market capitalization of $166.53 billion, a price-to-earnings ratio of 24.64, a price-to-earnings-growth ratio of 1.97 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the business posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were issued a $0.47 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend was Friday, March 13th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.